Rodolfo A. Ahuad Guerrero

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aldo P. Maggioni, Sally Greene, Gregg C. Fonarow et al. · European Heart Journal · 2013 · 56 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Prospective validation of EuroSCORE II in patients undergoing cardiac surgery in Argentinean centres

Raúl A. Borracci, Miguel Rubio, Leonardo Celano et al. · Interactive Cardiovascular and Thoracic Surgery · 2014 · 46 citations · Full text

Medicine, Perioperative Medicine, Surgery +14

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17